Article Text
Statistics from Altmetric.com
- Stratified medicine
- gene association
- platelets
- genetics
- risk factors
- coronary hemodynamics
- coronary intervention (PCI)
- non-coronary intervention
- myocardial ischaemia and infarction (IHD)
- pharmacology
The Authors' reply We thank Dr Jeong and colleagues for their comments1 regarding the incidence of dual high on-treatment platelet reactivity in patients undergoing elective percutaneous coronary intervention and its impact on clinical outcome.2 They raise several important issues.
First, they provide additional information on the optimal cut-off value of the VerifyNow platelet function test to detect high on-aspirin platelet reactivity. Due to a lack of consensus on the optimal method to quantify high on-aspirin platelet reactivity and on the cut-off value associated with clinical risk, the measurement of platelet reactivity has not been widely implemented and included in the guidelines. Furthermore, the correlation between platelet function tests is moderate and …
Footnotes
Linked article 301129.
Funding Siemens Healthcare Diagnostics provided the Dade PFA Collagen/ADP Test Cartridge and the novel INNOVANCE PFA P2Y* free-of-charge in the POPular study. Siemens Healthcare Diagnostics was not involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; or in the preparation, review and approval of the manuscript.
Competing interests JWvW received speaker's fee from Accumetrics and Siemens, Consultancy, The Medicines Company; JMtB received speaker's fee from Sanofi-Aventis, Eli Lilly, BMS and MSD, Consultancy Sanofi-Aventis, Schering-Plough and Glaxo Smith Kline.
Ethics approval This study was conducted with the approval of the Verenigde Commissie Mensgebonden Onderzoek.
Provenance and peer review Commissioned; internally peer reviewed.